first
influenza
pandem
centuri
pandem
taught
us
mani
lesson
influenza
viru
rel
mild
pathogen
major
patient
although
patient
develop
progress
sever
pneumonia
requir
hospit
next
influenza
pandem
predict
aris
near
futur
tremend
advanc
made
develop
antiinfluenza
drug
last
decad
howev
therapeut
effect
guarante
need
administ
agent
earli
onset
emerg
resist
viru
strain
addit
protect
effect
product
avail
influenza
vaccin
also
limit
situat
underli
press
need
defin
novel
therapeut
target
involv
diseas
pathogenesi
progress
excess
cytokin
product
consid
key
contributor
pathophysiolog
sever
influenza
infect
shi
et
al
report
inhibit
tumor
necrosi
factoralpha
etanercept
agent
provid
protect
infect
mice
inhibit
inflammatori
cytokin
therefor
repres
promis
novel
strategi
influenza
infect
studi
focus
high
mobil
group
origin
identifi
ubiquit
dnabind
protein
also
recogn
damageassoci
molecular
pattern
molecul
propos
crucial
mediat
pathogenesi
mani
diseas
includ
sepsi
autoimmun
acut
lung
inflamm
sever
sever
viral
infect
releas
passiv
necrot
cell
andor
activ
secret
macrophag
monocyt
extracellular
milieu
extracellular
elicit
product
proinflammatori
cytokin
induc
inflammatori
respons
sever
immun
receptor
includ
tolllik
receptor
receptor
advanc
glycat
end
product
rage
moreov
intranuclear
also
report
play
signific
role
replic
influenza
virus
recent
found
monoclon
antibodi
mab
markedli
inhibit
fluid
percussioninduc
brain
edema
rat
inhibit
transloc
result
prompt
us
evalu
therapeut
effect
mab
administr
sever
pneumonia
induc
influenza
viru
anticip
develop
drug
provid
compel
data
demonstr
mab
may
provid
novel
effect
pharmacolog
therapeut
strategi
sever
influenza
viru
infect
reduc
inflammatori
respons
induc
studi
approv
anim
use
committe
okayama
univers
graduat
school
medicin
dentistri
pharmaceut
scienc
conduct
accord
nation
institut
health
guidelin
eightweekold
male
mice
g
bodi
weight
purchas
charl
river
laboratori
yokohama
japan
hous
specificpathogenfre
anim
facil
lightdark
cycl
fed
standard
pellet
diet
orient
mf
orient
yeast
ltd
tokyo
japan
influenza
viru
apuerto
mouseadapt
strain
use
throughout
studi
viru
propag
embryon
chicken
egg
viru
titer
quantit
plaqu
assay
use
canin
kidney
cell
mous
lethal
dose
plaqueform
unit
pfu
nineweekold
mice
anesthet
intraperiton
inject
ketamin
mgkg
pentobarbit
mgkg
inocul
intranas
pfu
suspend
steril
phosphatebuff
salin
anim
allow
recov
analyz
describ
day
viru
inocul
defin
day
mice
randomli
assign
two
group
viru
inocul
mab
immunoglobulin
subclass
mgkg
classmatch
control
mab
antikeyhol
limpet
hemocyanin
administ
intraven
via
caudal
vein
hr
viru
inocul
mab
produc
group
describ
previous
dose
mab
mgkgmous
consid
suffici
larger
dose
mgkgmous
reduc
level
cytokin
lung
inject
mab
triplic
viru
inocul
level
remain
elev
observ
period
day
surviv
observ
day
mice
per
group
paramet
measur
mice
patholog
analys
perform
day
inocul
mice
per
group
time
point
mice
human
euthan
blood
bronchoalveolar
lavag
fluid
balf
sampl
measur
cytokin
chemokin
hydroperoxid
surgic
procedur
patholog
analysi
lung
histolog
examin
perform
describ
previous
immunohistochem
analysi
perform
use
antibodi
granulocytedifferenti
antigen
biolegend
san
diego
ca
usa
detect
neutrophil
infiltr
lung
accord
manufactur
instruct
lung
injuri
score
calcul
previous
describ
briefli
four
readili
identifi
patholog
process
grade
semiquantit
scale
alveolar
interstiti
edema
hemorrhag
margin
infiltr
inflammatori
cell
format
bronchiol
score
repres
normal
lung
repres
mild
moder
sever
denot
sever
chang
mous
lung
injuri
score
calcul
ad
individu
grade
mean
valu
five
section
categori
histolog
review
two
pathologist
blind
manner
nn
sf
bronchoalveolar
lavag
perform
previous
describ
briefli
right
lung
lavag
ml
cold
phosphatebuff
salin
recov
balf
collect
centrifug
supernat
store
prior
cytokin
analysi
total
cell
number
balf
calcul
cell
number
sediment
percentag
neutrophil
determin
total
neutrophil
number
balf
calcul
express
per
anim
total
rna
extract
middl
portion
left
lung
use
rneasi
plu
mini
qiagen
hilden
germani
total
rna
reversetranscrib
cdna
use
retroscript
appli
biosystem
foster
citi
ca
usa
accord
manufactur
instruct
briefli
total
rna
combin
random
decam
heat
minut
rnarandom
decam
mixtur
combin
revers
transcriptas
buffer
dntp
mix
rnase
inhibitor
moloney
murin
leukemia
viru
revers
transcriptas
rna
reversetranscrib
minut
enzym
inactiv
minut
cdna
use
templat
pcr
use
realtim
pcr
system
appli
biosystem
probe
primer
analysi
express
influenza
viru
type
gene
mrna
follow
taqman
probe
forward
primer
revers
primer
genbank
analysi
signal
pathway
perform
realtim
pcr
sybr
premix
ex
taq
takara
biomed
shiga
japan
accord
manufactur
protocol
sens
antisens
primer
use
analysi
express
mrna
follow
dehydrogenas
gapdh
genbank
rage
genbank
genbank
express
gapdh
use
normal
cdna
level
pcr
product
also
analyz
melt
curv
analysi
ascertain
specif
amplif
level
rage
measur
use
commerci
avail
enzymelink
immunosorb
assay
kit
shinotest
kanagawa
japan
rage
r
system
minneapoli
mn
usa
interleukin
chemokin
cxc
motif
ligand
measur
mous
cytokinechemokinemagnet
bead
panel
millipor
billerica
usa
luminex
system
millipor
serum
concentr
hydroperoxid
whole
oxid
capac
serum
n
ndiethylparaphenylenediamin
acid
buffer
measur
describ
previous
measur
unit
carr
u
previous
establish
carr
u
correspond
mg
hydrogen
peroxidedl
data
express
mean
sem
comparison
perform
u
test
use
prism
softwar
graphpad
softwar
san
diego
ca
usa
p
valu
differ
surviv
determin
logrank
mantelcox
test
p
consid
statist
signific
mice
inocul
pfu
influenza
viru
treat
mab
mgkg
intraven
protect
influenzainduc
death
wherea
infect
mice
administ
control
mab
die
fig
subsequ
viral
load
determin
lung
homogen
mice
began
die
day
time
point
day
inocul
select
follow
measur
differ
number
viral
rna
copi
lung
time
point
examin
mabtreat
mice
control
mabtreat
mice
upon
infect
fig
infect
mabtreat
mice
significantli
lower
level
serum
balf
time
point
examin
compar
control
mice
fig
control
mice
present
diffus
edema
inflammatori
cellular
infiltr
alveoli
interstitium
lung
hemorrhag
thicken
airway
treatment
mab
attenu
histopatholog
chang
evid
lung
fig
addit
mab
significantli
reduc
lung
injuri
score
compar
control
mice
day
inocul
fig
histolog
influenza
viru
inocul
increas
neutrophil
infiltr
lung
although
mab
treatment
attenu
effect
fig
neutrophil
number
balf
increas
mab
control
group
howev
neutrophil
number
remain
significantli
lower
mice
treat
mab
compar
control
mab
day
inocul
fig
result
indic
mab
treatment
significantli
suppress
neutrophil
infiltr
lung
mice
investig
balf
demonstr
mabtreat
mice
significantli
lower
product
day
inocul
compar
control
mice
fig
reversetranscript
pcr
lung
homogen
show
mabtreat
mice
significantli
attenu
rage
express
day
viru
inocul
compar
control
mice
fig
addit
mrna
analysi
measur
rage
protein
level
balf
mabtreat
mice
control
mice
inocul
enzymelink
immunosorb
assay
mabtreat
mice
significantli
lower
product
rage
day
inocul
fig
serum
concentr
hydroperoxid
also
significantli
lower
mabtreat
mice
compar
control
mice
time
point
examin
fig
result
indic
mab
treatment
attenu
oxid
stress
observ
mice
battl
sever
influenza
clinician
begin
recogn
immun
respons
patient
modul
involv
inflammatori
mediat
pathogenesi
influenza
recogn
major
issu
first
shown
addit
function
late
mediat
endotoxin
lethal
sinc
reveal
protein
inflammatori
cytokin
activ
pathogenesi
influenza
well
mani
inflammatori
diseas
recent
attract
attent
mani
research
therapeut
target
treatment
variou
diseas
sever
research
alreadi
investig
influenza
suggest
antiinfluenza
effect
differ
inhibitori
agent
includ
ethyl
pyruv
chines
herb
studi
evalu
therapeut
effect
mab
sever
pneumonia
mice
initi
establish
influenzainduc
mous
model
pneumonia
lethal
subsequ
mgkg
mab
administ
intraven
inject
triplic
viru
inocul
result
demonstr
system
suppress
normal
basal
level
mab
could
protect
sever
pneumonia
almost
complet
surviv
also
show
mab
attenu
rage
express
suggest
rage
play
import
role
pathophysiolog
mechan
mab
hou
et
al
recent
report
effect
rabbit
polyclon
antibodi
influenza
infect
howev
report
identifi
protect
mechan
antibodi
influenza
infect
find
reveal
effect
mab
influenza
infect
lower
dose
administ
intraven
compar
studi
hou
et
al
antibodi
use
studi
monoclon
recogn
ctermin
sequenc
use
mab
previous
demonstr
benefici
effect
differ
type
inflammatori
diseas
ischem
traumat
brain
injuri
primari
structur
conserv
amino
acid
sequenc
homolog
rodent
human
therefor
result
studi
may
applic
influenza
infect
human
moreov
also
develop
human
mab
data
shown
consequ
studi
signific
step
forward
clinic
applic
mab
divers
rang
inflammatori
diseas
human
includ
tissu
injuri
cytokin
chemokin
contribut
overal
patholog
lung
injuri
sever
well
document
pneumonia
found
mice
mab
significantli
suppress
local
product
key
cytokin
orchestr
pathophysiolog
highli
virul
influenza
strain
rapidli
releas
acut
phase
influenza
infect
elev
level
associ
diseas
sever
trigger
infect
shown
correl
morbid
mortal
influenzainfect
subject
moreov
level
also
significantli
suppress
mice
treat
mab
chemokin
direct
traffick
circul
neutrophil
site
inflamm
injuri
effect
cytokin
chemokin
help
explain
observ
decreas
local
inflammatori
respons
attenu
infiltr
neutrophil
improv
surviv
inocul
mabtreat
mice
key
find
treatment
mab
result
suppress
express
rage
rage
primari
bind
receptor
interact
rage
induc
inflammatori
respons
via
activ
van
zoelen
et
al
previous
report
import
rage
pathogenesi
influenzainduc
pneumonia
pulmonari
rage
upregul
associ
influenzainduc
pneumonia
ragedefici
mice
show
increas
resist
influenzainduc
pneumonia
addit
signal
result
express
rage
via
posit
feedback
loop
therefor
treatment
mab
could
restrict
rage
express
pneumonia
block
signal
result
suppress
inflammatori
respons
interestingli
howev
attenu
rage
express
seen
earli
phase
infect
day
mabtreat
mice
although
level
suppress
significantli
serum
balf
time
point
correspondingli
signific
differ
express
two
group
later
phase
infect
day
find
help
explain
observ
cytokin
differ
significantli
express
two
group
later
phase
infect
solubl
rage
srage
might
provid
key
answer
paradox
found
studi
rage
level
balf
srage
significantli
higher
control
mice
mabtreat
mice
without
transmembran
domain
srage
report
circul
cell
act
decoy
prevent
ligand
includ
bind
rage
therefor
function
neg
feedback
rage
interact
ligand
hyperexpress
srage
balf
might
result
decreas
cytokin
level
research
downstream
signal
pathway
axi
influenzainduc
pneumonia
warrant
clarifi
specul
signal
involv
influenza
infect
addit
rage
one
receptor
therefor
possibl
neutral
may
affect
express
lead
alter
cytokin
respons
lung
signal
may
induc
deleteri
effect
therefor
measur
level
express
lung
mab
treatment
result
neutral
affect
express
lung
compar
control
addit
file
thu
like
signal
directli
involv
alter
cytokin
respons
lung
patholog
mab
treatment
believ
ragemedi
signal
import
model
test
hypothesi
specif
rage
antibodi
could
use
small
interf
rna
specif
rage
could
employ
shown
mice
rage
defici
protect
influenza
viru
infect
studi
necessari
address
point
anoth
key
find
studi
mab
treatment
attenu
serum
concentr
hydroperoxid
mice
find
indic
treatment
mab
might
contribut
comprehens
suppress
local
cytokin
chemokin
also
system
oxid
stress
group
recent
report
administr
redoxact
protein
amelior
pneumonia
mice
via
antioxid
properti
suggest
antioxid
strategi
may
key
therapeut
regimen
influenzainduc
pneumonia
therefor
also
import
assess
oxid
stress
respons
influenzainduc
pneumonia
howev
find
warrant
studi
yet
studi
antioxid
mechan
mab
although
sever
viral
pneumonia
tend
rare
outbreak
season
influenza
mani
case
primari
viral
pneumonia
observ
recent
influenza
pandem
especi
young
even
pandem
world
face
rise
burden
viral
respiratori
infect
includ
highli
pathogen
avian
influenza
sever
acut
respiratori
syndromeassoci
coronaviru
middl
east
respiratori
syndrom
coronaviru
acut
respiratori
distress
syndrom
caus
new
virus
immedi
challeng
also
report
associ
pathogenesi
acut
respiratori
distress
syndrom
given
limit
benefit
antivir
drug
mab
provid
protect
effect
host
immunolog
respons
shine
new
light
treatment
emerg
viral
infect
intraven
administr
mab
significantli
improv
surviv
rate
attenu
lung
histopatholog
chang
murin
model
influenzainduc
pneumonia
protect
effect
mab
might
explain
blockad
interact
rage
key
mechan
initi
inflammatori
oxid
respons
result
suggest
mab
repres
possibl
therapeut
pharmacolog
strategi
sever
influenzainduc
pneumonia
human
intraven
administr
monoclon
antibodi
significantli
improv
surviv
rate
attenu
lung
histopatholog
chang
murin
model
influenzainduc
pneumoniaintraven
monoclon
antibodi
inhibit
system
local
level
suppress
inflammatori
cytokinechemokin
express
oxid
stress
observ
miceth
express
receptor
advanc
glycat
end
product
rage
attenu
monoclon
antibodi
treatment
